SHP-201 / Shape Therapeutics - LARVOL DELTA

Shape Therapeutics Receives Research Grant from The Michael J. Fox Foundation for Parkinson’s Research to Advance SHP-201, a One-Time Gene Therapy to Treat Parkinson’s Disease (The Manila Times) - "The award will support preclinical studies characterizing the pharmacology, pharmacokinetics, and safety of SHP-201 to enable a subsequent Investigational New Drug (IND) submission for clinical trials."

Financing • Parkinson's Disease

TARGETED KNOCKDOWN OF ALPHA SYNUCLEIN IN THE DEEP BRAIN SUPPORTS THE THERAPEUTIC DEVELOPMENT OF SHP-201 FOR PARKINSON'S DISEASE (ADPD 2026) - "SHP-201 enabled robust and specific knockdown of aSyn protein in vitro and in vivo. Intravenous delivery of SHP-201 elicited substantial knockdown of SNCA across the NHP brain, with maximal activity observed in the Substantia nigra, a critical region in PD. These data highlight the strong potential therapeutic benefit of SHP-201 and support its continued development."

CNS Disorders • Movement Disorders • Parkinson's Disease • SNCA

Shape Therapeutics Shares Breakthrough Preclinical Data for Non-Invasive Treatment of Parkinson’s Disease Using a Brain Targeted AAV Gene Therapy at the European Society of Gene & Cell Therapy 32nd Annual Congress (GlobeNewswire) - "AAV5 exhibits substantially lower seroprevalence, offering a more favorable immune profile. SHP-DB1 was created through a multi-stage screen of over 1 billion AAV capsids in non-human primates (NHPs), followed by iterative optimization. The capsid incorporates additional engineering that enhances post-entry trafficking and boosts payload expression in transduced cells, overcoming an intrinsic limitation of AAV5...Most strikingly, SHP-DB1 achieves 96% neuronal transduction in the substantia nigra, a critical region for Parkinson’s Disease therapy...SHP-201 appears to be very well tolerated in vivo across species..."

Preclinical • Parkinson's Disease